SAN JOSE, Calif., Dec. 11, 2019 /PRNewswire/ -- Anpac Bio-Medical Science Co., Ltd. ("Anpac Bio" or the "Company") announced today the appointment of Professor Michael Levitt of Stanford University to be the Chief Consultant of Anpac Bio's Innovation and Technical Advisory Board. Dr. Levitt received the 2013 Nobel Prize in Chemistry for the development of multiscale models for complex chemical systems. Dr. Levitt's role will be to help strengthen Anpac Bio's patented CDA (Cancer-Differentiation Analysis) technology, which can detect the risk of up to 26 cancer types using a single blood test. Anpac Bio provides its CDA tests commercially in China and is currently working to enter the market in the United States.
Anpac Bio's Chairman and CEO, Chris Yu, commented, "Anpac is excited to be working with Dr. Levitt on our ground-breaking technology. Our innovative biophysical approach to cancer screening and detection is complementary with Dr. Levitt's background in quantum mechanics, chemistry, and structural biology. We believe that Dr. Levitt's contributions will help us to achieve further market penetration in China and will assist us in our entrance in the United States through clinical trials and additional academic collaborations."
More on The Californer
Dr. Levitt has previously served on the Scientific Advisory Boards of DuPont Merck Pharmaceuticals, AMGEN, PDL Biopharma, as well as many other well-known companies throughout his career. Dr. Levitt received his PhD from Cambridge University in 1972 and was a postdoctoral scholar at the Weizmann Institute of Science in Israel from 1972 to 1974. Dr. Levitt joined the Department of Structural Biology at Stanford in 1987.
About Anpac Bio
Anpac Bio is a biotechnology company focused on early cancer screening and detection. With two certified clinical laboratories in China, Anpac Bio performs a suite of cancer screening and detection tests, including CDA, bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, Anpac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. These clinical samples demonstrated that Anpac Bio's CDA technology could detect the risk of over 20 different cancer types with high sensitivity and specificity. https://www.anpacbio.com/
More on The Californer
Safe Harbor Statement
This announcement contains forward-looking statements, including statements about the Company's business outlook, strategy and market opportunity, and statements that may suggest trends for its business. These statements are individually and collectively forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made only as of the date of this announcement and are based on estimates and information available to the Company at the time of this announcement. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and may be beyond the Company's control. Therefore, prospective investors are cautioned that actual results may differ materially from those set forth in any forward-looking statements herein. Except as otherwise required by applicable securities laws, the Company disclaims any intention or obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE AnPac Bio-Medical Science Co., Ltd.
Related Links
https://www.anpacbio.com
Anpac Bio's Chairman and CEO, Chris Yu, commented, "Anpac is excited to be working with Dr. Levitt on our ground-breaking technology. Our innovative biophysical approach to cancer screening and detection is complementary with Dr. Levitt's background in quantum mechanics, chemistry, and structural biology. We believe that Dr. Levitt's contributions will help us to achieve further market penetration in China and will assist us in our entrance in the United States through clinical trials and additional academic collaborations."
More on The Californer
- San Francisco: Mayor London Breed Announces Policy Changes to Increase Usage of Substance Use Treatment Beds
- San Francisco: Mayor London Breed Accepts Win-Win Playoff Challenge from Mayor Eric Genrich of Green Bay
- California: Governor Newsom Issues Proclamation Declaring Lunar New Year 1.24.20
- Why Did My Car Insurance Go Up?
- Megha Dontha Narrates Audiobook Version of Best-Selling Startup Book 'The 60 Minute Startup'
Dr. Levitt has previously served on the Scientific Advisory Boards of DuPont Merck Pharmaceuticals, AMGEN, PDL Biopharma, as well as many other well-known companies throughout his career. Dr. Levitt received his PhD from Cambridge University in 1972 and was a postdoctoral scholar at the Weizmann Institute of Science in Israel from 1972 to 1974. Dr. Levitt joined the Department of Structural Biology at Stanford in 1987.
About Anpac Bio
Anpac Bio is a biotechnology company focused on early cancer screening and detection. With two certified clinical laboratories in China, Anpac Bio performs a suite of cancer screening and detection tests, including CDA, bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, Anpac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. These clinical samples demonstrated that Anpac Bio's CDA technology could detect the risk of over 20 different cancer types with high sensitivity and specificity. https://www.anpacbio.com/
More on The Californer
- Fire Disaster Response Team at Guzi-West Helps Property Owners Navigate the Cleanup Process
- BTI Completes OSHA 10 Training
- San Francisco: Mayor London Breed Announces Policy Changes to Increase Usage of Substance Use Treatment Beds
- IAOP and The Rockefeller Foundation Announce Winners of 2020 Global Impact Sourcing Award
- Thought Provoking Consulting announces new hires to its 3D Digital Transformation practice
Safe Harbor Statement
This announcement contains forward-looking statements, including statements about the Company's business outlook, strategy and market opportunity, and statements that may suggest trends for its business. These statements are individually and collectively forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made only as of the date of this announcement and are based on estimates and information available to the Company at the time of this announcement. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and may be beyond the Company's control. Therefore, prospective investors are cautioned that actual results may differ materially from those set forth in any forward-looking statements herein. Except as otherwise required by applicable securities laws, the Company disclaims any intention or obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE AnPac Bio-Medical Science Co., Ltd.
Related Links
https://www.anpacbio.com
Filed Under: Business
0 Comments
Latest on The Californer
- California: Governor Newsom and Senate President Pro Tempore Atkins Join Volunteers for San Diego's Point-In-Time Homeless Count
- Nutrient Technologies, Inc. Expanding Fertilizer Research
- Mayor London Breed Celebrates Opening of San Francisco's First Housing Program for Transgender Adults
- The Pediatric Cancer Research Foundation Funds 6 New Research Grants In 2020
- How Entrepreneurs Can Run A "Lifestyle Business" Writing One Email A Day
- AutoQuotes Appoints New Chief Product Officer
- Limelight Health Wins 2020 BIG Innovation Award
- TurboTax Starts the New Decade by Empowering Latino Tax Filers Through Integrated Marketing Campaign
- Two join the Plymouth, MA-based Hart Speech Foundation Board of Directors
- The Legacy of Jack LaLanne, The Godfather of Fitness, Introduced to a New Generation
- Family of Man Killed in Conception Boat Fire Tragedy Files in the CONCEPTION Limitation Action
- Help with Sleep Apnea Disorder & Sleep Apnea Treatment- San Ramon Dental Excellence
- Maxeler Technologies Licenses Healthcare Technologies
- New Ascorbate Oxidase from Molecular Depot
- New Human Myoglobin Antibody and Antigen from Molecular Depot
- California: Governor Newsom Appoints Government Operations Agency, Business, Consumer Services and Housing Agency, and Veterans Affairs Secretaries
- Greenlit Content Partners With Wizard World To Bring Esports To Pop Culture Events In 2020
- Satanic Child Trafficking Nightmare Distraction On Capitol Hill
- California: Governor Newsom Announces Deployment of Trailers and Medical Services Tents to Los Angeles County as Part of Accelerated State Action on Homelessness
- Announcing 2020 Race Roster of Awesome Experiences